These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22949140)

  • 21. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
    Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N
    Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A proposed treatment algorithm for adults with Haemoglobin SC disease.
    Naessens V; Ward R; Kuo KHM
    Br J Haematol; 2018 Aug; 182(4):607-609. PubMed ID: 28699645
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P; Barretto de Mello A; Figueiredo MS
    Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of hydroxyurea on hemoglobin S].
    Torres AF; Eberle SE; Sciuccati G; Bonduel M
    Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyurea for sickle cell disease.
    Davies S; Olujohungbe A
    Cochrane Database Syst Rev; 2001; (2):CD002202. PubMed ID: 11406036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
    Ansari SH; Shamsi TS; Siddiqui FJ; Irfan M; Perveen K; Farzana T; Panjwani VK; Yousuf A; Mehboob T
    J Pediatr Hematol Oncol; 2007 Nov; 29(11):743-6. PubMed ID: 17984691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clustering.
    Dahoui HA; Hayek MN; Nietert PJ; Arabi MT; Muwakkit SA; Saab RH; Bissar AN; Jumaa NM; Farhat FS; Dabbous IA; Bitar FF; Abboud MR
    Pediatr Blood Cancer; 2010 Mar; 54(3):398-402. PubMed ID: 19827138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of hydroxyurea on vasculopathy in a child with sickle cell disease.
    Helton KJ; Wang WC; Wynn LW; Khan RB; Steen RG
    AJNR Am J Neuroradiol; 2002; 23(10):1692-6. PubMed ID: 12427625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
    Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
    Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
    Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F
    Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ten-year review of hospital admissions among children with sickle cell disease in Kuwait.
    Akar NA; Adekile A
    Med Princ Pract; 2008; 17(5):404-8. PubMed ID: 18685282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute chest syndrome is associated with history of asthma in hemoglobin SC disease.
    Poulter EY; Truszkowski P; Thompson AA; Liem RI
    Pediatr Blood Cancer; 2011 Aug; 57(2):289-93. PubMed ID: 21671365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM; Ebert BL
    Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
    Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
    Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insights into elevated distortion product otoacoustic emissions in sickle cell disease: comparisons of hydroxyurea-treated and non-treated young children.
    Stuart A; Jones SM; Walker LJ
    Hear Res; 2006 Feb; 212(1-2):83-9. PubMed ID: 16364581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Most adults with severe HbSC disease are not treated with hydroxyurea.
    Ghunney WK; Asare EV; Ayete-Nyampong JB; Oppong SA; Rodeghier M; DeBaun MR; Olayemi E
    Blood Adv; 2023 Jul; 7(13):3312-3319. PubMed ID: 36799926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.